|
gptkbp:instanceOf
|
gptkb:drug
gptkb:monoclonal_antibody
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XC24
|
|
gptkbp:brand
|
gptkb:Darzalex_Faspro
gptkb:Darzalex
|
|
gptkbp:CASNumber
|
945721-28-8
|
|
gptkbp:combines
|
gptkb:dexamethasone
gptkb:lenalidomide
gptkb:bortezomib
gptkb:pomalidomide
|
|
gptkbp:developedBy
|
gptkb:Janssen_Biotech
gptkb:Genmab
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:halfLife
|
18 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daratumumab
|
|
gptkbp:immunoglobulinType
|
gptkb:IgG1_kappa
|
|
gptkbp:indication
|
relapsed or refractory multiple myeloma
newly diagnosed multiple myeloma
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
binds to CD38 on plasma cells
|
|
gptkbp:molecularWeight
|
148 kDa
|
|
gptkbp:origin
|
gptkb:human
|
|
gptkbp:pharmacokinetics
|
linear
|
|
gptkbp:pregnancyCategory
|
not recommended
|
|
gptkbp:PubChem_CID
|
DB09331
|
|
gptkbp:routeOfAdministration
|
subcutaneous
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
nausea
fatigue
thrombocytopenia
infusion reactions
|
|
gptkbp:target
|
gptkb:CD38
|
|
gptkbp:UNII
|
82ZZY92T6T
|
|
gptkbp:usedFor
|
multiple myeloma
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Genmab
gptkb:Genmab_A/S
|
|
gptkbp:bfsLayer
|
7
|